Anavex Life Sciences Corp. (LON:0HFR)

Anavex Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cash & Equivalents	120.78	132.19	151.02	149.16	152.11	29.25
Cash & Short-Term Investments	120.78	132.19	151.02	149.16	152.11	29.25
Cash Growth	-15.99%	-12.47%	1.25%	-1.94%	420.04%	31.84%
Other Receivables	2.56	2.45	2.71	3.19	9.14	4.85
Receivables	2.56	2.45	2.71	3.19	9.14	4.85
Prepaid Expenses	0.71	0.93	0.65	0.35	0.37	0.44
Total Current Assets	124.04	135.57	154.39	152.71	161.62	34.54
Total Assets	124.04	135.57	154.39	152.71	161.62	34.54
Accounts Payable	4.57	9.63	4.32	3.83	4.74	3.99
Accrued Expenses	7.73	4.84	7.3	5.95	5.61	3.32
Current Unearned Revenue	0.83	0.84	0.92	0.44	0.44	-
Total Current Liabilities	13.13	15.3	12.53	10.21	10.8	7.31
Total Liabilities	13.13	15.3	12.53	10.21	10.8	7.31
Common Stock	0.09	0.09	0.08	0.08	0.08	0.06
Additional Paid-In Capital	459.01	456.25	434.84	387.98	348.33	186.85
Retained Earnings	-348.18	-336.07	-293.07	-245.56	-197.59	-159.68
Shareholders' Equity	110.92	120.26	141.85	142.49	150.82	27.24
Total Liabilities & Equity	124.04	135.57	154.39	152.71	161.62	34.54
Net Cash (Debt)	120.78	132.19	151.02	149.16	152.11	29.25
Net Cash Growth	-15.99%	-12.47%	1.25%	-1.94%	420.04%	31.84%
Net Cash Per Share	1.44	1.58	1.89	1.94	2.18	0.50
Filing Date Shares Outstanding	85.06	84.82	82.09	77.96	76.02	66.96
Total Common Shares Outstanding	84.99	84.8	82.07	77.94	75.92	62.05
Working Capital	110.92	120.26	141.85	142.49	150.82	27.24
Book Value Per Share	1.31	1.42	1.73	1.83	1.99	0.44
Tangible Book Value	110.92	120.26	141.85	142.49	150.82	27.24
Tangible Book Value Per Share	1.31	1.42	1.73	1.83	1.99	0.44

Source: S&P Capital IQ. Standard template. Financial Sources.